{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:55:31Z","timestamp":1792547731537,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41585-024-00857-z","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:03:52Z","timestamp":1708355032000},"page":"495-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeting histone modifiers in bladder cancer therapy \u2014 preclinical and clinical evidence"],"prefix":"10.1038","volume":"21","author":[{"given":"Shiyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-0495","authenticated-orcid":false,"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-3577","authenticated-orcid":false,"given":"Ping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-3042","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"857_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"857_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/his.13734","volume":"74","author":"MJ Magers","year":"2019","unstructured":"Magers, M. J. et al. Staging of bladder cancer. Histopathology 74, 112\u2013134 (2019).","journal-title":"Histopathology"},{"key":"857_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234\u2013241 (2013).","journal-title":"Eur. Urol."},{"key":"857_CR4","doi-asserted-by":"publisher","unstructured":"Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. D. Bladder cancer. JAMA 324, 1980\u20131991 https:\/\/doi.org\/10.1001\/jama.2020.17598 (2020).","DOI":"10.1001\/jama.2020.17598"},{"key":"857_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle\u2010invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404\u2013423 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"857_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"857_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JU.0000000000000593","volume":"203","author":"CR Ritch","year":"2020","unstructured":"Ritch, C. R. et al. Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J. Urol. 203, 505\u2013511 (2020).","journal-title":"J. Urol."},{"key":"857_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch, S. & Alfred Witjes, J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60, 493\u2013500 (2011).","journal-title":"Eur. Urol."},{"key":"857_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ccr.2004.08.002","volume":"6","author":"CP Dinney","year":"2004","unstructured":"Dinney, C. P. et al. Focus on bladder cancer. Cancer Cell 6, 111\u2013116 (2004).","journal-title":"Cancer Cell"},{"key":"857_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"857_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","volume":"108","author":"FA Yafi","year":"2011","unstructured":"Yafi, F. A. et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 108, 539\u2013545 (2011).","journal-title":"BJU Int."},{"key":"857_CR13","doi-asserted-by":"crossref","unstructured":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202\u2013205; discussion 205\u2013206 (2005).","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"857_CR14","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432\u20132438 (2011).","journal-title":"J. Clin. Oncol."},{"key":"857_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952\u2013959 (2017).","journal-title":"Eur. Urol."},{"key":"857_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2020","unstructured":"Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E. & Theodorescu, D. Advances in bladder cancer biology and therapy. Nat. Rev. Cancer 21, 104\u2013121 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell 128, 693\u2013705 (2007).","journal-title":"Cell"},{"key":"857_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","volume":"153","author":"H Shen","year":"2013","unstructured":"Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38\u201355 (2013).","journal-title":"Cell"},{"key":"857_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrc2931","volume":"10","author":"AA Mills","year":"2010","unstructured":"Mills, A. A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 10, 669\u2013682 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487\u2013500 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"857_CR21","doi-asserted-by":"publisher","first-page":"120946","DOI":"10.1016\/j.lfs.2022.120946","volume":"308","author":"N Cheshmazar","year":"2022","unstructured":"Cheshmazar, N. et al. Current trends in development of HDAC-based chemotherapeutics. Life Sci. 308, 120946 (2022).","journal-title":"Life Sci."},{"key":"857_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrd.2016.256","volume":"16","author":"SX Pfister","year":"2017","unstructured":"Pfister, S. X. & Ashworth, A. Marked for death: targeting epigenetic changes in cancer. Nat. Rev. Drug Discov. 16, 241\u2013263 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"857_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"857_CR24","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.2174\/0929867324666170207142740","volume":"24","author":"M Pinkerneil","year":"2017","unstructured":"Pinkerneil, M., Hoffmann, M. J., Schulz, W. A. & Niegisch, G. HDACs and HDAC inhibitors in urothelial carcinoma \u2014 perspectives for an antineoplastic treatment. Curr. Med. Chem. 24, 4151\u20134165 (2017).","journal-title":"Curr. Med. Chem."},{"key":"857_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"857_CR26","doi-asserted-by":"publisher","first-page":"eaai8312","DOI":"10.1126\/scitranslmed.aai8312","volume":"9","author":"LD Ler","year":"2017","unstructured":"Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci. Transl. Med. 9, eaai8312 (2017).","journal-title":"Sci. Transl. Med."},{"key":"857_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/science.aba8347","volume":"370","author":"RJ Andrew","year":"2020","unstructured":"Andrew, R. J. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75\u201382 (2020).","journal-title":"Science"},{"key":"857_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network.","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"857_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"857_CR30","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.3390\/cancers13236040","volume":"13","author":"MJ Hoffmann","year":"2021","unstructured":"Hoffmann, M. J. & Schulz, W. A. Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma. Cancers 13, 6040 (2021).","journal-title":"Cancers"},{"key":"857_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1464-410X.2009.08795.x","volume":"105","author":"A Ozawa","year":"2010","unstructured":"Ozawa, A. et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int. 105, 1181\u20131186 (2010).","journal-title":"BJU Int."},{"key":"857_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/1535-7163.MCT-15-0618","volume":"15","author":"M Pinkerneil","year":"2016","unstructured":"Pinkerneil, M. et al. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol. Cancer Ther. 15, 299\u2013312 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"857_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/bfgp\/els065","volume":"12","author":"V Di Cerbo","year":"2013","unstructured":"Di Cerbo, V. & Schneider, R. Cancers with wrong HATs: the impact of acetylation. Brief. Funct. Genomics 12, 231\u2013243 (2013).","journal-title":"Brief. Funct. Genomics"},{"key":"857_CR34","doi-asserted-by":"publisher","first-page":"a018762","DOI":"10.1101\/cshperspect.a018762","volume":"6","author":"R Marmorstein","year":"2014","unstructured":"Marmorstein, R. & Zhou, M. M. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6, a018762 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"857_CR35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/ijms18071449","volume":"18","author":"EA Koutsogiannouli","year":"2017","unstructured":"Koutsogiannouli, E. A. et al. Differential effects of histone acetyltransferase GCN5 or PCAF knockdown on urothelial carcinoma cells. Int. J. Mol. Sci. 18, 1449 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"857_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/emboj.2010.318","volume":"30","author":"Q Jin","year":"2011","unstructured":"Jin, Q. et al. Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation. EMBO J. 30, 249\u2013262 (2011).","journal-title":"EMBO J."},{"key":"857_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e525 (2017).","journal-title":"Cell"},{"key":"857_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","volume":"67","author":"PH Kim","year":"2015","unstructured":"Kim, P. H. et al. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur. Urol. 67, 198\u2013201 (2015).","journal-title":"Eur. Urol."},{"key":"857_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","volume":"75","author":"EJ Pietzak","year":"2019","unstructured":"Pietzak, E. J. et al. Genomic differences between \u201cPrimary\u201d and \u201cSecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur. Urol. 75, 231\u2013239 (2019).","journal-title":"Eur. Urol."},{"key":"857_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","volume":"6","author":"H Ogiwara","year":"2016","unstructured":"Ogiwara, H. et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 6, 430\u2013445 (2016).","journal-title":"Cancer Discov."},{"key":"857_CR41","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.7150\/ijbs.32332","volume":"15","author":"J Li","year":"2019","unstructured":"Li, J. et al. A CRISPR interference of CBP and p300 selectively induced synthetic lethality in bladder cancer cells in vitro. Int. J. Biol. Sci. 15, 1276\u20131286 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"857_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1097-2765(00)80452-9","volume":"5","author":"DL Ontario","year":"2000","unstructured":"Ontario, D. L. et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 5, 589\u2013595 (2000).","journal-title":"Mol. Cell"},{"key":"857_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/10409238.2011.557713","volume":"46","author":"P Rajendran","year":"2011","unstructured":"Rajendran, P., Williams, D. E., Ho, E. & Dashwood, R. H. Metabolism as a key to histone deacetylase inhibition. Crit. Rev. Biochem. Mol. Biol. 46, 181\u2013199 (2011).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"857_CR44","first-page":"12","volume":"119","author":"M Alivand","year":"2018","unstructured":"Alivand, M. et al. Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer. Bratisl. Lek. Listy 119, 12\u201316 (2018).","journal-title":"Bratisl. Lek. Listy"},{"key":"857_CR45","volume":"13","author":"P Ce\u0301dric","year":"2014","unstructured":"Ce\u0301dric, P. et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin. Pathol. 13, 10 (2014).","journal-title":"BMC Clin. Pathol."},{"key":"857_CR46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4161\/cc.10.3.14712","volume":"10","author":"J Jurkin","year":"2011","unstructured":"Jurkin, J. et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10, 406\u2013412 (2011).","journal-title":"Cell Cycle"},{"key":"857_CR47","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1042\/BST20130010","volume":"41","author":"RD Kelly","year":"2013","unstructured":"Kelly, R. D. & Cowley, S. M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem. Soc. Trans. 41, 741\u2013749 (2013).","journal-title":"Biochem. Soc. Trans."},{"key":"857_CR48","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","volume":"31","author":"G Niegisch","year":"2013","unstructured":"Niegisch, G. et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. 31, 1770\u20131779 (2013).","journal-title":"Urol. Oncol."},{"key":"857_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-022-01319-0","volume":"9","author":"AA Jaguva Vasudevan","year":"2022","unstructured":"Jaguva Vasudevan, A. A. et al. Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression. Sci. Data 9, 240 (2022).","journal-title":"Sci. Data"},{"key":"857_CR50","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/ijms20092135","volume":"20","author":"AA Jaguva Vasudevan","year":"2019","unstructured":"Jaguva Vasudevan, A. A. et al. HDAC5 expression in urothelial carcinoma cell lines inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition. Int. J. Mol. Sci. 20, 2135 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"857_CR51","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.1021\/ja102758v","volume":"132","author":"KV Butler","year":"2010","unstructured":"Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842\u201310846 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"857_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3892\/ol.2020.12315","volume":"21","author":"H Kuroki","year":"2020","unstructured":"Kuroki, H. et al. Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment. Oncol. Lett. 21, 64 (2020).","journal-title":"Oncol. Lett."},{"key":"857_CR53","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.18632\/oncotarget.22816","volume":"9","author":"S Ota","year":"2018","unstructured":"Ota, S., Zhou, Z. Q. & Hurlin, P. J. Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities. Oncotarget 9, 3172\u20133187 (2018).","journal-title":"Oncotarget"},{"key":"857_CR54","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4161\/cbt.28469","volume":"15","author":"L Rosik","year":"2014","unstructured":"Rosik, L. et al. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol. Ther. 15, 742\u2013757 (2014).","journal-title":"Cancer Biol. Ther."},{"key":"857_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0224-3","volume":"8","author":"V Carafa","year":"2016","unstructured":"Carafa, V. et al. Sirtuin functions and modulation: from chemistry to the clinic. Clin. Epigenetics 8, 61 (2016).","journal-title":"Clin. Epigenetics"},{"key":"857_CR56","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrc3985","volume":"15","author":"A Chalkiadaki","year":"2015","unstructured":"Chalkiadaki, A. & Guarente, L. The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15, 608\u2013624 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"857_CR57","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/cancers12051066","volume":"12","author":"S Monteiro-Reis","year":"2020","unstructured":"Monteiro-Reis, S. et al. Sirtuins\u2019 deregulation in bladder cancer: SIRT7 is implicated in tumor progression through epithelial to mesenchymal transition promotion. Cancers 12, 1066 (2020).","journal-title":"Cancers"},{"key":"857_CR58","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1038\/s41388-021-01999-9","volume":"40","author":"P Tan","year":"2021","unstructured":"Tan, P. et al. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene 40, 6081\u20136092 (2021).","journal-title":"Oncogene"},{"key":"857_CR59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s13577-019-00237-5","volume":"32","author":"J Chen","year":"2019","unstructured":"Chen, J., Cao, L., Li, Z. & Li, Y. SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. Hum. Cell 32, 193\u2013201 (2019).","journal-title":"Hum. Cell"},{"key":"857_CR60","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411001992","volume":"13","author":"S Muller","year":"2011","unstructured":"Muller, S., Filippakopoulos, P. & Knapp, S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29 (2011).","journal-title":"Expert Rev. Mol. Med."},{"key":"857_CR61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","volume":"149","author":"P Filippakopoulos","year":"2012","unstructured":"Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214\u2013231 (2012).","journal-title":"Cell"},{"key":"857_CR62","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","volume":"26","author":"N Zaware","year":"2019","unstructured":"Zaware, N. & Zhou, M. M. Bromodomain biology and drug discovery. Nat. Struct. Mol. Biol. 26, 870\u2013879 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"857_CR63","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-15-0750","volume":"15","author":"X Wu","year":"2016","unstructured":"Wu, X. et al. BRD4 regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer. Mol. Cancer Ther. 15, 1029\u20131042 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"857_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1139\/bcb-2021-0552","volume":"100","author":"T Liu","year":"2022","unstructured":"Liu, T., Zhang, Z., Wang, C., Huang, H. & Li, Y. BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance. Biochem. Cell Biol. 100, 179\u2013187 (2022).","journal-title":"Biochem. Cell Biol."},{"key":"857_CR65","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","volume":"66","author":"N Huang","year":"2023","unstructured":"Huang, N., Liao, P., Zuo, Y., Zhang, L. & Jiang, R. Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 inhibitor for the treatment of some solid tumors. J. Med. Chem. 66, 2646\u20132662 (2023).","journal-title":"J. Med. Chem."},{"key":"857_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0434-3","volume":"10","author":"AS H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher, A. S., Schulz, W. A., Pinkerneil, M., Niegisch, G. & Hoffmann, M. J. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Clin. Epigenetics 10, 1 (2018).","journal-title":"Clin. Epigenetics"},{"key":"857_CR67","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nrm1761","volume":"6","author":"C Martin","year":"2005","unstructured":"Martin, C. & Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838\u2013849 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"857_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2006.07.009","volume":"89","author":"P V\u00f6lkel","year":"2007","unstructured":"V\u00f6lkel, P. & Angrand, P. O. The control of histone lysine methylation in epigenetic regulation. Biochimie 89, 1\u201320 (2007).","journal-title":"Biochimie"},{"key":"857_CR69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s000180050127","volume":"54","author":"T Jenuweina","year":"1998","unstructured":"Jenuweina, T., Laiblea, G., Dornb, R. & Reuterb, G. SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol. Life Sci. 54, 80\u201393 (1998).","journal-title":"Cell Mol. Life Sci."},{"key":"857_CR70","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","volume":"112","author":"J Min","year":"2003","unstructured":"Min, J., Feng, Q., Li, Z., Zhang, Y. & Xu, R. M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112, 711\u2013723 (2003).","journal-title":"Cell"},{"key":"857_CR71","first-page":"165","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y., Ge, K., Li, T., Cai, R. & Chen, Y. The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications. Protein Cell 14, 165\u2013179 (2023).","journal-title":"Protein Cell"},{"key":"857_CR72","doi-asserted-by":"publisher","first-page":"11871","DOI":"10.1073\/pnas.1606857113","volume":"113","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition. Proc. Natl Acad. Sci. USA 113, 11871\u201311876 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR73","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846821","volume":"20","author":"T Rampias","year":"2019","unstructured":"Rampias, T. et al. The lysine-specific methyltransferase KMT2C\/MLL3 regulates DNA repair components in cancer. EMBO Rep. 20, e46821 (2019).","journal-title":"EMBO Rep."},{"key":"857_CR74","doi-asserted-by":"publisher","first-page":"108924","DOI":"10.1016\/j.biopha.2019.108924","volume":"115","author":"P Sun","year":"2019","unstructured":"Sun, P. et al. KMT2D inhibits the growth and metastasis of bladder cancer cells by maintaining the tumor suppressor genes. Biomed. Pharmacother. 115, 108924 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"857_CR75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1101\/gad.306241.117","volume":"32","author":"E Lin-Shiao","year":"2018","unstructured":"Lin-Shiao, E. et al. KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis. Genes Dev. 32, 181\u2013193 (2018).","journal-title":"Genes Dev."},{"key":"857_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eururo.2020.11.008","volume":"79","author":"SC Baker","year":"2021","unstructured":"Baker, S. C., Mason, A. S. & Southgate, J. Does a novel mutagenic process target KMT2D mutation in the most common first event on the path to bladder cancer? Eur. Urol. 79, 435\u2013436 (2021).","journal-title":"Eur. Urol."},{"key":"857_CR77","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1126\/science.aba7300","volume":"370","author":"R Li","year":"2020","unstructured":"Li, R. et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 370, 82\u201389 (2020).","journal-title":"Science"},{"key":"857_CR78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.abe0955","volume":"370","author":"SG Rozen","year":"2020","unstructured":"Rozen, S. G. Mutational selection in normal urothelium. Science 370, 34\u201335 (2020).","journal-title":"Science"},{"key":"857_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206098","volume":"10","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. KMT2D deficiency promotes myeloid leukemias which is vulnerable to ribosome biogenesis inhibition. Adv. Sci. 10, e2206098 (2023).","journal-title":"Adv. Sci."},{"key":"857_CR80","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"857_CR81","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1073\/pnas.1116418109","volume":"109","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989\u20132994 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR82","doi-asserted-by":"publisher","first-page":"eabo8043","DOI":"10.1126\/sciadv.abo8043","volume":"8","author":"Andrea Piunti","year":"2022","unstructured":"Andrea Piunti et al. Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci. Adv. 8, eabo8043 (2022).","journal-title":"Sci. Adv."},{"key":"857_CR83","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","volume":"37","author":"D Fantini","year":"2018","unstructured":"Fantini, D. et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene 37, 1911\u20131925 (2018).","journal-title":"Oncogene"},{"key":"857_CR84","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03854474 (2023)."},{"key":"857_CR85","doi-asserted-by":"publisher","first-page":"25309","DOI":"10.1074\/jbc.M101914200","volume":"276","author":"M Tachibana","year":"2001","unstructured":"Tachibana, M., Sugimoto, K., Fukushima, T. & Shinkai, Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276, 25309\u201325317 (2001).","journal-title":"J. Biol. Chem."},{"key":"857_CR86","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","volume":"6","author":"F Casciello","year":"2015","unstructured":"Casciello, F., Windloch, K., Gannon, F. & Lee, J. S. Functional role of G9a histone methyltransferase in cancer. Front. Immunol. 6, 487 (2015).","journal-title":"Front. Immunol."},{"key":"857_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138390","volume":"10","author":"F Li","year":"2015","unstructured":"Li, F. et al. G9a inhibition induces autophagic cell death via AMPK\/mTOR pathway in bladder transitional cell carcinoma. PLoS ONE\u00a010, e0138390 (2015).","journal-title":"PLoS ONE"},{"key":"857_CR88","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41401-018-0205-5","volume":"40","author":"YP Cao","year":"2019","unstructured":"Cao, Y. P. et al. Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells. Acta Pharmacol. Sin. 40, 1076\u20131084 (2019).","journal-title":"Acta Pharmacol. Sin."},{"key":"857_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15424","volume":"8","author":"E San Jose-Eneriz","year":"2017","unstructured":"San Jose-Eneriz, E. et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat. Commun. 8, 15424 (2017).","journal-title":"Nat. Commun."},{"key":"857_CR90","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","volume":"25","author":"C Segovia","year":"2019","unstructured":"Segovia, C. et al. Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression. Nat. Med. 25, 1073\u20131081 (2019).","journal-title":"Nat. Med."},{"key":"857_CR91","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.18632\/oncotarget.14453","volume":"8","author":"S Cristina","year":"2017","unstructured":"Cristina, S. et al. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget 8, 10531\u201310542 (2017).","journal-title":"Oncotarget"},{"key":"857_CR92","first-page":"1157","volume":"17","author":"G Hu","year":"2018","unstructured":"Hu, G., Wang, X., Han, Y. & Wang, P. Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis. EXCLI J. 17, 1157\u20131166 (2018).","journal-title":"EXCLI J."},{"key":"857_CR93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13046-022-02500-4","volume":"41","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. J. Exp. Clin. Cancer Res. 41, 293 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"857_CR94","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941\u2013953 (2004).","journal-title":"Cell"},{"key":"857_CR95","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.25349","volume":"128","author":"S Hayami","year":"2011","unstructured":"Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574\u2013586 (2011).","journal-title":"Int. J. Cancer"},{"key":"857_CR96","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436\u2013439 (2005).","journal-title":"Nature"},{"key":"857_CR97","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/mc.20758","volume":"50","author":"EC Kauffman","year":"2011","unstructured":"Kauffman, E. C. et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50, 931\u2013944 (2011).","journal-title":"Mol. Carcinog."},{"key":"857_CR98","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fonc.2020.01234","volume":"10","author":"Q Xie","year":"2020","unstructured":"Xie, Q. et al. LSD1 promotes bladder cancer progression by upregulating LEF1 and enhancing EMT. Front. Oncol. 10, 1234 (2020).","journal-title":"Front. Oncol."},{"key":"857_CR99","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/onc.2017.13","volume":"36","author":"W Wan","year":"2017","unstructured":"Wan, W. et al. Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1\u03b1. Oncogene 36, 3868\u20133877 (2017).","journal-title":"Oncogene"},{"key":"857_CR100","doi-asserted-by":"publisher","first-page":"E179","DOI":"10.1002\/ijc.26501","volume":"131","author":"HS Cho","year":"2012","unstructured":"Cho, H. S. et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1\/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int. J. Cancer 131, E179\u2013E189 (2012).","journal-title":"Int. J. Cancer"},{"key":"857_CR101","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrg1726","volume":"6","author":"JC Pearson","year":"2005","unstructured":"Pearson, J. C., Lemons, D. & McGinnis, W. Modulating Hox gene functions during animal body patterning. Nat. Rev. Genet. 6, 893\u2013904 (2005).","journal-title":"Nat. Rev. Genet."},{"key":"857_CR102","doi-asserted-by":"publisher","first-page":"154141","DOI":"10.1016\/j.prp.2022.154141","volume":"239","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. HOXA1 promotes proliferation and metastasis of bladder cancer by enhancing SMAD3 transcription. Pathol. Res. Pract. 239, 154141 (2022).","journal-title":"Pathol. Res. Pract."},{"key":"857_CR103","doi-asserted-by":"publisher","first-page":"188747","DOI":"10.1016\/j.bbcan.2022.188747","volume":"1877","author":"M Belpaire","year":"2022","unstructured":"Belpaire, M., Taminiau, A., Geerts, D. & Rezsohazy, R. HOXA1, a breast cancer oncogene. Biochim. Biophys. Acta Rev. Cancer 1877, 188747 (2022).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"857_CR104","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-12-4300","volume":"73","author":"WL Berry","year":"2013","unstructured":"Berry, W. L. & Janknecht, R. KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 73, 2936\u20132942 (2013).","journal-title":"Cancer Res."},{"key":"857_CR105","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2013.04.009","volume":"336","author":"M Kogure","year":"2013","unstructured":"Kogure, M. et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G1\/S transition. Cancer Lett. 336, 76\u201384 (2013).","journal-title":"Cancer Lett."},{"key":"857_CR106","first-page":"1431","volume":"42","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Upregulation of JMJD2A promotes migration and invasion in bladder cancer through regulation of SLUG. Oncol. Rep. 42, 1431\u20131440 (2019).","journal-title":"Oncol. Rep."},{"key":"857_CR107","doi-asserted-by":"publisher","first-page":"18439","DOI":"10.1073\/pnas.0707292104","volume":"104","author":"S Hong","year":"2007","unstructured":"Hong, S. et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl Acad. Sci. USA 104, 18439\u201318444 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR108","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","volume":"81","author":"A Shilatifard","year":"2012","unstructured":"Shilatifard, A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81, 65\u201395 (2012).","journal-title":"Annu. Rev. Biochem."},{"key":"857_CR109","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-0330","volume":"20","author":"ML Nickerson","year":"2014","unstructured":"Nickerson, M. L. et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin. Cancer Res. 20, 4935\u20134948 (2014).","journal-title":"Clin. Cancer Res."},{"key":"857_CR110","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ng.907","volume":"43","author":"Y Gui","year":"2011","unstructured":"Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875\u2013878 (2011).","journal-title":"Nat. Genet."},{"key":"857_CR111","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","volume":"25","author":"AH Nassar","year":"2019","unstructured":"Nassar, A. H. et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin. Cancer Res. 25, 2458\u20132470 (2019).","journal-title":"Clin. Cancer Res."},{"key":"857_CR112","doi-asserted-by":"publisher","first-page":"eaar5598","DOI":"10.1126\/sciadv.aar5598","volume":"4","author":"S Kaneko","year":"2018","unstructured":"Kaneko, S., Li, X. X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci. Adv. 4, eaar5598 (2018).","journal-title":"Sci. Adv."},{"key":"857_CR113","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G van Haaften","year":"2009","unstructured":"van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521\u2013523 (2009).","journal-title":"Nat. Genet."},{"key":"857_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01369-9","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol. Cancer 20, 77 (2021).","journal-title":"Mol. Cancer"},{"key":"857_CR115","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1073\/pnas.0810094106","volume":"106","author":"W Yimin","year":"2009","unstructured":"Yimin, W. et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc. Natl Acad. Sci. USA 106, 5807\u20135812 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112696119","volume":"119","author":"N Kong","year":"2022","unstructured":"Kong, N. et al. Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. Proc. Natl Acad. Sci. USA 119, e2112696119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR117","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nature06145","volume":"449","author":"K Agger","year":"2007","unstructured":"Agger, K. et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731\u2013734 (2007).","journal-title":"Nature"},{"key":"857_CR118","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41418-019-0278-9","volume":"26","author":"S Ramakrishnan","year":"2019","unstructured":"Ramakrishnan, S. et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death Differ. 26, 2100\u20132114 (2019).","journal-title":"Cell Death Differ."},{"key":"857_CR119","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","volume":"26","author":"K Kobatake","year":"2020","unstructured":"Kobatake, K. et al. Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction. Clin. Cancer Res. 26, 2065\u20132079 (2020).","journal-title":"Clin. Cancer Res."},{"key":"857_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2017.04.005","volume":"316","author":"KK Goswami","year":"2017","unstructured":"Goswami, K. K. et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell Immunol. 316, 1\u201310 (2017).","journal-title":"Cell Immunol."},{"key":"857_CR121","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"857_CR122","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/bs.apcsb.2019.08.005","volume":"117","author":"SS Chaturvedi","year":"2019","unstructured":"Chaturvedi, S. S., Ramanan, R., Waheed, S. O., Karabencheva-Christova, T. G. & Christov, C. Z. Structure-function relationships in KDM7 histone demethylases. Adv. Protein Chem. Struct. Biol. 117, 113\u2013125 (2019).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"857_CR123","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.3390\/ijms21165658","volume":"21","author":"KH Lee","year":"2020","unstructured":"Lee, K. H. et al. Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells. Int. J. Mol. Sci. 21, 5658 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"857_CR124","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/ijc.31843","volume":"143","author":"KH Lee","year":"2018","unstructured":"Lee, K. H. et al. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. Int. J. Cancer 143, 2849\u20132861 (2018).","journal-title":"Int. J. Cancer"},{"key":"857_CR125","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41585-023-00761-y","volume":"20","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. The androgen receptor in bladder cancer. Nat. Rev. Urol. 20, 560\u2013574 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"857_CR126","doi-asserted-by":"publisher","first-page":"13419","DOI":"10.1074\/jbc.M609809200","volume":"282","author":"JH Lee","year":"2007","unstructured":"Lee, J. H., Tate, C. M., You, J. S. & Skalnik, D. G. Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. J. Biol. Chem. 282, 13419\u201313428 (2007).","journal-title":"J. Biol. Chem."},{"key":"857_CR127","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3389\/fonc.2018.00502","volume":"8","author":"K Lu","year":"2018","unstructured":"Lu, K., Tao, H., Si, X. & Chen, Q. The histone H3 lysine 4 presenter WDR5 as an oncogenic protein and novel epigenetic target in cancer. Front. Oncol. 8, 502 (2018).","journal-title":"Front. Oncol."},{"key":"857_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/srep08293","volume":"5","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. Sci. Rep. 5, 8293 (2015).","journal-title":"Sci. Rep."},{"key":"857_CR129","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nchembio.1859","volume":"11","author":"F Grebien","year":"2015","unstructured":"Grebien, F. et al. Pharmacological targeting of the Wdr5-MLL interaction in C\/EBP\u03b1 N-terminal leukemia. Nat. Chem. Biol. 11, 571\u2013578 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"857_CR130","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13046-021-01989-5","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J. Exp. Clin. Cancer Res. 40, 203 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"857_CR131","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","volume":"175","author":"X Huang","year":"2018","unstructured":"Huang, X. et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell 175, 186\u2013199 e119 (2018).","journal-title":"Cell"},{"key":"857_CR132","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad, H. P., Barbash, O. & Creasy, C. L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat. Med. 25, 403\u2013418 (2019).","journal-title":"Nat. Med."},{"key":"857_CR133","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"857_CR134","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.aat0383","volume":"359","author":"E Ghorani","year":"2018","unstructured":"Ghorani, E. & Quezada, S. A. Chromatin regulation and immune escape. Science 359, 745\u2013746 (2018).","journal-title":"Science"},{"key":"857_CR135","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598\u2013607 (2011).","journal-title":"Cancer Discov."},{"key":"857_CR136","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70, 440\u2013446 (2010).","journal-title":"Cancer Res"},{"key":"857_CR137","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","volume":"22","author":"H Zheng","year":"2016","unstructured":"Zheng, H. et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22, 4119\u20134132 (2016).","journal-title":"Clin. Cancer Res."},{"key":"857_CR138","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774\u201311779 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR139","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion, A. et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin. Cancer Res. 23, 5187\u20135201 (2017).","journal-title":"Clin. Cancer Res."},{"key":"857_CR140","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods, D. M. et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res. 3, 1375\u20131385 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"857_CR141","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114, E10981\u2013e10990 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR142","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","volume":"68","author":"D Llopiz","year":"2019","unstructured":"Llopiz, D. et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol. Immunother. 68, 379\u2013393 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"857_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42237-3","volume":"9","author":"T Knox","year":"2019","unstructured":"Knox, T. et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci. Rep. 9, 6136 (2019).","journal-title":"Sci. Rep."},{"key":"857_CR144","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","volume":"67","author":"D Briere","year":"2018","unstructured":"Briere, D. et al. The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol. Immunother. 67, 381\u2013392 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"857_CR145","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imm.12136","volume":"140","author":"KA Cycon","year":"2013","unstructured":"Cycon, K. A., Mulvaney, K., Rimsza, L. M., Persky, D. & Murphy, S. P. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 140, 259\u2013272 (2013).","journal-title":"Immunology"},{"key":"857_CR146","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1189\/jlb.0209056","volume":"86","author":"H Jensen","year":"2009","unstructured":"Jensen, H., Andresen, L., Hansen, K. A. & Skov, S. Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity. J. Leukoc. Biol. 86, 923\u2013932 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"857_CR147","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fonc.2020.00699","volume":"10","author":"B Burke","year":"2020","unstructured":"Burke, B. et al. Inhibition of histone deacetylase (HDAC) enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction. Front. Oncol. 10, 699 (2020).","journal-title":"Front. Oncol."},{"key":"857_CR148","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","volume":"78","author":"R Saito","year":"2018","unstructured":"Saito, R. et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 78, 3954\u20133968 (2018).","journal-title":"Cancer Res."},{"key":"857_CR149","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138560","volume":"131","author":"AS Truong","year":"2021","unstructured":"Truong, A. S. et al. Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. J. Clin. Invest. 131, e138560 (2021).","journal-title":"J. Clin. Invest."},{"key":"857_CR150","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00045006 (2013)."},{"key":"857_CR151","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413075 (2015)."},{"key":"857_CR152","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00363883 (2015)."},{"key":"857_CR153","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/cncr.31817","volume":"125","author":"P Grivas","year":"2019","unstructured":"Grivas, P. et al. Mocetinostat for patients with previously treated, locally advanced\/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer 125, 533\u2013540 (2019).","journal-title":"Cancer"},{"key":"857_CR154","unstructured":"US ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02619253 (2023)."},{"key":"857_CR155","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/JCO.2019.37.15_suppl.2572","volume":"37","author":"P Roberto","year":"2019","unstructured":"Roberto, P. et al. Immunomodulation by HDAC inhibition: results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients. J. Clin. Oncol. 37, 2572\u20132572 (2019).","journal-title":"J. Clin. Oncol."},{"key":"857_CR156","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00565227 (2016)."},{"key":"857_CR157","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03978624 (2023)."},{"key":"857_CR158","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00421889 (2015)."},{"key":"857_CR159","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/2159-8290.CD-NB2020-006","volume":"10","author":"M Leslie","year":"2020","unstructured":"Leslie, M. First EZH2 inhibitor approved \u2014 for rare sarcoma. Cancer Discov. 10, 333\u2013334 (2020).","journal-title":"Cancer Discov."},{"key":"857_CR160","doi-asserted-by":"publisher","first-page":"TPS607","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS607","volume":"38","author":"J Joshua","year":"2020","unstructured":"Joshua, J. et al. A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183). J. Clin. Oncol. 38, TPS607 (2020).","journal-title":"J. Clin. Oncol."},{"key":"857_CR161","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia, J. E. & Campbell, R. M. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol. 8, a019521 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"857_CR162","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature03117","volume":"432","author":"S Chuikov","year":"2004","unstructured":"Chuikov, S. et al. Regulation of p53 activity through lysine methylation. Nature 432, 353\u2013360 (2004).","journal-title":"Nature"},{"key":"857_CR163","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","volume":"23","author":"E Kim","year":"2013","unstructured":"Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839\u2013852 (2013).","journal-title":"Cancer Cell"},{"key":"857_CR164","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"X Kexin","year":"2012","unstructured":"Kexin, X. et al. Oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465\u20131469 (2012).","journal-title":"Science"},{"key":"857_CR165","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molcel.2013.08.028","volume":"52","author":"HY Jung","year":"2013","unstructured":"Jung, H. Y. et al. PAF and EZH2 induce Wnt\/\u03b2-catenin signaling hyperactivation. Mol. Cell 52, 193\u2013205 (2013).","journal-title":"Mol. Cell"},{"key":"857_CR166","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1073\/pnas.1308953111","volume":"111","author":"ME Gonzalez","year":"2014","unstructured":"Gonzalez, M. E. et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl Acad. Sci. USA 111, 3098\u20133103 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"857_CR167","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm.3968","volume":"21","author":"KH Kim","year":"2015","unstructured":"Kim, K. H. et al. SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491\u20131496 (2015).","journal-title":"Nat. Med."},{"key":"857_CR168","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380 (2017).","journal-title":"Science"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00857-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T13:11:47Z","timestamp":1722604307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00857-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":168,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00857-z","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"15 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}